CDK8/19 inhibitors for therapy of advanced prostate cancer

Ended Project Grant Awarded Last action

Award ID
R44CA203184
Recipient
Awarding agency
Obligated
$1,977,275

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Place of performance
Columbia, SC 29208, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment CDK8/19 inhibitors for therapy of advanced prostate cancer - the growth of most prostate cancers is driven by androgen receptor (AR), a transcriptional… $846,340
Original award $1,130,935

Quick answers

Who received award R44CA203184?

R44CA203184 was awarded to Senex Biotechnology Inc. by National Cancer Institute (National Institutes of Health) on May 13, 2020.

How much is award R44CA203184 worth?

$1,977,275 has been obligated on R44CA203184.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award